BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33465286)

  • 1. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
    Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
    Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
    Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
    Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
    Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
    Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
    Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
    Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
    Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
    Miyamoto Y; Suyama K; Baba H
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Validation of Plasma-Based Genotyping for
    Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
    JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
    Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri LM; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
    Int J Cancer; 2024 Feb; 154(3):488-503. PubMed ID: 37724848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
    Cohen R; Liu H; Fiskum J; Adams R; Chibaudel B; Maughan TS; Van Cutsem E; Venook A; Douillard JY; Heinemann V; Ja Punt C; Falcone A; Bokemeyer C; Kaplan R; Lenz HJ; Koopman M; Yoshino T; Zalcberg J; Grothey A; de Gramont A; Shi Q; André T
    J Natl Cancer Inst; 2021 Oct; 113(10):1386-1395. PubMed ID: 33734401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS and BRAF in metastatic colorectal cancer management.
    Gong J; Cho M; Fakih M
    J Gastrointest Oncol; 2016 Oct; 7(5):687-704. PubMed ID: 27747083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
    Raghav K; Ou FS; Venook AP; Innocenti F; Sun R; Lenz HJ; Kopetz S
    J Clin Oncol; 2023 Jan; 41(3):472-478. PubMed ID: 36067452
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series.
    Okunaka M; Kotani D; Mishima S; Nakamura M; Kawazoe A; Bando H; Yoshino T; Shitara K
    Integr Cancer Ther; 2024; 23():15347354231225962. PubMed ID: 38240253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.
    Muendlein A; Geiger K; Heinzle C; Gaenger S; Winder T; Severgnini L; Reimann P; Brandtner EM; Leiherer A; Drexel H; Decker T; Nonnenbroich C; Dechow T
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6435-6444. PubMed ID: 36763171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer.
    Bai M; Lu Y; Shi C; Yang J; Li W; Yin X; Huang C; Shen L; Xie L; Ba Y
    Cancer Biol Med; 2023 Dec; ():. PubMed ID: 38148327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
    Pinto TDA; Alves TDDN; Pinto SA; Oliveira EC
    Arq Bras Cir Dig; 2021; 34(1):e1574. PubMed ID: 34133521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies.
    Rachiglio AM; Forgione L; Pasquale R; Barone CA; Maiello E; Antonuzzo L; Cassata A; Tonini G; Bordonaro R; Rosati G; Zaniboni A; Lonardi S; Ferrari D; Frassineti GL; Tamberi S; Pisconti S; Di Fabio F; Roma C; Orlandi A; Latiano T; Damato A; Tortora G; Pinto C; Normanno N
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese expert consensus on maintenance treatment with anti-EGFR monoclonal antibody for
    Committee of Colorectal Experts, Chinese Society of Clinical Oncology
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):316-325. PubMed ID: 38644236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
    Randon G; Nakamura Y; Yaeger R; Lonardi S; Cremolini C; Elez E; Nichetti F; Ghelardi F; Nasca V; Bergamo F; Conca V; Ros J; Bando H; Maddalena G; Oldani S; Prisciandaro M; Raimondi A; Schrock AB; Agnelli L; Walch H; Yoshino T; Pietrantonio F
    Clin Cancer Res; 2024 Jan; 30(2):436-443. PubMed ID: 37610454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.